The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC).
A. Gucalp
No relevant relationships to disclose
S. M. Tolaney
No relevant relationships to disclose
S. J. Isakoff
No relevant relationships to disclose
J. N. Ingle
No relevant relationships to disclose
M. C. Liu
No relevant relationships to disclose
L. A. Carey
No relevant relationships to disclose
K. L. Blackwell
Consultant or Advisory Role - Biosystems International
H. S. Rugo
No relevant relationships to disclose
L. Nabell
No relevant relationships to disclose
A. Abbruzzi
No relevant relationships to disclose
J. Gonzalez
No relevant relationships to disclose
D. D. Giri
No relevant relationships to disclose
S. Patil
No relevant relationships to disclose
K. Feigin
No relevant relationships to disclose
G. D'Andrea
No relevant relationships to disclose
M. Theodoulou
No relevant relationships to disclose
P. Drullinsky
No relevant relationships to disclose
N. T. Sklarin
No relevant relationships to disclose
C. Hudis
No relevant relationships to disclose
T. A. Traina
No relevant relationships to disclose